FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond

Centre for Personalized Response Monitoring in Oncology (PREMIO)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

49 Downloads (Pure)

Resumé

While current international guidelines include imaging of the target lesion for response monitoring in metastatic breast cancer, they do not provide specific recommendations for choice of imaging modality or response criteria. This is important as clinical decisions may vary depending on which imaging modality is used for monitoring metastatic breast cancer. FDG-PET/CT has shown high accuracy in diagnosing metastatic breast cancer, and the Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) have shown higher predictive values than the CT-based Response Evaluation Criteria in Solid Tumors (RECIST) for prediction of progression-free survival. No studies have yet addressed the clinical impact of using different imaging modalities or response evaluation criteria for longitudinal response monitoring in metastatic breast cancer. We present a case study of a patient with metastatic breast cancer who was monitored first with conventional CT and then with FDG-PET/CT. We retrospectively applied PERCIST to evaluate the longitudinal response to treatment. We used the one-lesion PERCIST model measuring SULpeak in the hottest metastatic lesion on consecutive scans. This model provides a continuous variable that allows graphical illustration of disease fluctuation along with response categories. The one-lesion PERCIST approach seems able to reflect molecular changes and has the potential to support clinical decision-making. Prospective clinical studies addressing the clinical impact of PERCIST in metastatic breast cancer are needed to establish evidence-based recommendations for response monitoring in this disease.

OriginalsprogEngelsk
Artikelnummer1190
TidsskriftCancers
Vol/bind11
Udgave nummer8
Antal sider13
ISSN2072-6694
DOI
StatusUdgivet - 15. aug. 2019

Fingeraftryk

Neoplasms
Disease-Free Survival
Prospective Studies
Guidelines
Response Evaluation Criteria in Solid Tumors
Clinical Studies
Clinical Decision-Making

Citer dette

Centre for Personalized Response Monitoring in Oncology (PREMIO) (2019). FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond. Cancers , 11(8), [1190]. https://doi.org/10.3390/cancers11081190
Centre for Personalized Response Monitoring in Oncology (PREMIO). / FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer : Today, Tomorrow, and Beyond. I: Cancers . 2019 ; Bind 11, Nr. 8.
@article{a7f001d5130a4edea2df3de8bb1a0fa7,
title = "FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond",
abstract = "While current international guidelines include imaging of the target lesion for response monitoring in metastatic breast cancer, they do not provide specific recommendations for choice of imaging modality or response criteria. This is important as clinical decisions may vary depending on which imaging modality is used for monitoring metastatic breast cancer. FDG-PET/CT has shown high accuracy in diagnosing metastatic breast cancer, and the Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) have shown higher predictive values than the CT-based Response Evaluation Criteria in Solid Tumors (RECIST) for prediction of progression-free survival. No studies have yet addressed the clinical impact of using different imaging modalities or response evaluation criteria for longitudinal response monitoring in metastatic breast cancer. We present a case study of a patient with metastatic breast cancer who was monitored first with conventional CT and then with FDG-PET/CT. We retrospectively applied PERCIST to evaluate the longitudinal response to treatment. We used the one-lesion PERCIST model measuring SULpeak in the hottest metastatic lesion on consecutive scans. This model provides a continuous variable that allows graphical illustration of disease fluctuation along with response categories. The one-lesion PERCIST approach seems able to reflect molecular changes and has the potential to support clinical decision-making. Prospective clinical studies addressing the clinical impact of PERCIST in metastatic breast cancer are needed to establish evidence-based recommendations for response monitoring in this disease.",
author = "Hildebrandt, {Malene Grubbe} and Lauridsen, {Jeppe Faurholdt} and Marianne Vogsen and Jorun Holm and Vilstrup, {Mie Holm} and Poul-Erik Braad and Oke Gerke and Mads Thomassen and Marianne Ewertz and H{\o}ilund-Carlsen, {Poul Flemming} and {Centre for Personalized Response Monitoring in Oncology (PREMIO)}",
year = "2019",
month = "8",
day = "15",
doi = "10.3390/cancers11081190",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI",
number = "8",

}

Centre for Personalized Response Monitoring in Oncology (PREMIO) 2019, 'FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond', Cancers , bind 11, nr. 8, 1190. https://doi.org/10.3390/cancers11081190

FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer : Today, Tomorrow, and Beyond. / Centre for Personalized Response Monitoring in Oncology (PREMIO).

I: Cancers , Bind 11, Nr. 8, 1190, 15.08.2019.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer

T2 - Today, Tomorrow, and Beyond

AU - Hildebrandt, Malene Grubbe

AU - Lauridsen, Jeppe Faurholdt

AU - Vogsen, Marianne

AU - Holm, Jorun

AU - Vilstrup, Mie Holm

AU - Braad, Poul-Erik

AU - Gerke, Oke

AU - Thomassen, Mads

AU - Ewertz, Marianne

AU - Høilund-Carlsen, Poul Flemming

AU - Centre for Personalized Response Monitoring in Oncology (PREMIO)

PY - 2019/8/15

Y1 - 2019/8/15

N2 - While current international guidelines include imaging of the target lesion for response monitoring in metastatic breast cancer, they do not provide specific recommendations for choice of imaging modality or response criteria. This is important as clinical decisions may vary depending on which imaging modality is used for monitoring metastatic breast cancer. FDG-PET/CT has shown high accuracy in diagnosing metastatic breast cancer, and the Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) have shown higher predictive values than the CT-based Response Evaluation Criteria in Solid Tumors (RECIST) for prediction of progression-free survival. No studies have yet addressed the clinical impact of using different imaging modalities or response evaluation criteria for longitudinal response monitoring in metastatic breast cancer. We present a case study of a patient with metastatic breast cancer who was monitored first with conventional CT and then with FDG-PET/CT. We retrospectively applied PERCIST to evaluate the longitudinal response to treatment. We used the one-lesion PERCIST model measuring SULpeak in the hottest metastatic lesion on consecutive scans. This model provides a continuous variable that allows graphical illustration of disease fluctuation along with response categories. The one-lesion PERCIST approach seems able to reflect molecular changes and has the potential to support clinical decision-making. Prospective clinical studies addressing the clinical impact of PERCIST in metastatic breast cancer are needed to establish evidence-based recommendations for response monitoring in this disease.

AB - While current international guidelines include imaging of the target lesion for response monitoring in metastatic breast cancer, they do not provide specific recommendations for choice of imaging modality or response criteria. This is important as clinical decisions may vary depending on which imaging modality is used for monitoring metastatic breast cancer. FDG-PET/CT has shown high accuracy in diagnosing metastatic breast cancer, and the Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) have shown higher predictive values than the CT-based Response Evaluation Criteria in Solid Tumors (RECIST) for prediction of progression-free survival. No studies have yet addressed the clinical impact of using different imaging modalities or response evaluation criteria for longitudinal response monitoring in metastatic breast cancer. We present a case study of a patient with metastatic breast cancer who was monitored first with conventional CT and then with FDG-PET/CT. We retrospectively applied PERCIST to evaluate the longitudinal response to treatment. We used the one-lesion PERCIST model measuring SULpeak in the hottest metastatic lesion on consecutive scans. This model provides a continuous variable that allows graphical illustration of disease fluctuation along with response categories. The one-lesion PERCIST approach seems able to reflect molecular changes and has the potential to support clinical decision-making. Prospective clinical studies addressing the clinical impact of PERCIST in metastatic breast cancer are needed to establish evidence-based recommendations for response monitoring in this disease.

U2 - 10.3390/cancers11081190

DO - 10.3390/cancers11081190

M3 - Journal article

C2 - 31443324

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 8

M1 - 1190

ER -

Centre for Personalized Response Monitoring in Oncology (PREMIO). FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond. Cancers . 2019 aug 15;11(8). 1190. https://doi.org/10.3390/cancers11081190